\n
Like many huge pharma corporations presently, Merck\u2019s greatest problem within the subsequent few years is the patent cliff. Merck has spent years getting ready for the lack of exclusivity dealing with Keytruda, however the scale of the issue continues to develop. Keytruda and its subcutaneous formulation Keytruda\u00a0Qlex\u00a0generated\u00a0round\u00a0$31.7 billion\u00a0in 2025,\u00a0practically half\u00a0of Merck\u2019s complete gross sales, whereas key U.S. patents defending pembrolizumab are on account of start expiring in 2028. The drug remains to be increasing into new most cancers settings and recorded double-digit progress within the first quarter of 2026.\u00a0<\/p>\n
Merck\u2019s current dealmaking means that it doesn’t count on one other drugs to interchange Keytruda by itself. In October 2025, the corporate accomplished its roughly\u00a0$10\u00a0billion\u00a0acquisition\u00a0of Verona Pharma, gaining Ohtuvayre, an already marketed therapy for persistent obstructive pulmonary illness. It adopted in January 2026 with the\u00a0$9.2 billion\u00a0acquisition\u00a0of\u00a0Cidara\u00a0Therapeutics and its part 3 influenza-prevention candidate MK-1406, earlier than agreeing in March to pay roughly\u00a0$6.7 billion\u00a0for\u00a0Terns Prescribed drugs\u00a0and the clinical-stage persistent myeloid leukemia drug TERN-701.\u00a0<\/p>\n
Shopping for property after a few of their improvement\u00a0danger has\u00a0fallen is hardly distinctive to Merck. With patent expiries approaching throughout the pharmaceutical trade, giant drugmakers are searching for merchandise that may attain the market shortly sufficient to assist their present companies. Merck\u2019s rising technique is extra distinctive in the way in which these acquisitions match round a number of more and more concentrated portfolios. Ohtuvayre joins\u00a0Winrevair\u00a0and\u00a0enlicitide\u00a0in cardio-pulmonary drugs; Merck\u2019s TERN-701 provides to a rising hematology pipeline; and MK-1406 enhances an\u00a0infectious\u00a0illness\u00a0portfolio more and more centered on long-acting therapy and prevention.\u00a0<\/p>\n
The focus downside Keytruda created\u00a0<\/h2>\n
When the U.S. Meals and Drug Administration (FDA) first authorized Keytruda in 2014, its use was restricted to sufferers with superior melanoma who had already acquired different therapies. The PD-1 inhibitor\u00a0subsequently\u00a0expanded throughout\u00a0quite a few\u00a0tumor varieties, therapy\u00a0strains\u00a0and mixtures, transferring from superior illness into earlier settings the place immunotherapy is given earlier than or after surgical procedure.\u00a0\u00a0<\/p>\n
Keytruda will not be behaving like a mature product approaching patent expiry but. Gross sales rose one other 12% yr on yr to roughly\u00a0$8 billion\u00a0within the first quarter of 2026. Demand continued to extend each in metastatic cancers and in earlier-stage indications similar to triple-negative breast, cervical and renal cell cancers. The franchise remains to be turning into bigger even because the interval through which Merck can depend on it’s shorter.\u00a0<\/p>\n
Merck\u00a0expects\u00a0biosimilar competitors to start affecting Keytruda materially between 2028 and 2029. Its main U.S. compound patent expires in December 2028, though two associated composition-of-matter patents prolong into 2029. European market exclusivity is anticipated to final till 2031.\u00a0\u00a0<\/p>\n
There are additionally pressures elsewhere within the portfolio. Gardasil and Gardasil 9 gross sales\u00a0fell\u00a039% to roughly\u00a0$5.2 billion\u00a0in 2025, largely due to decrease demand and extra stock in China. Merck had paused shipments to the nation in February 2025 and later prolonged that pause by the tip of the yr.\u00a0\u00a0<\/p>\n
Newer merchandise are starting to broaden the income base, however they\u00a0stay\u00a0removed from Keytruda\u2019s scale.\u00a0Winrevair\u00a0gross sales\u00a0virtually doubled\u00a0yr on yr to $525 million within the first quarter of 2026, whereas the lately launched Keytruda\u00a0Qlex\u00a0generated $128 million.\u00a0\u00a0<\/p>\n
Keytruda\u00a0isn\u2019t\u00a0an bizarre patent expiry because it has been, and nonetheless is, Merck\u2019s progress engine. Merck\u00a0has to\u00a0unwind a enterprise mannequin through which one drugs provides virtually half of the corporate\u2019s income, whereas its second-largest franchise has additionally change into much less reliable.\u00a0<\/p>\n
Cardio-pulmonary drugs turns into Merck\u2019s clearest second pillar\u00a0<\/h2>\n
Amongst Merck\u2019s companies past oncology, cardio-pulmonary drugs presently appears to be the clearest new progress pillar taking form.\u00a0Winrevair\u00a0has\u00a0established\u00a0a specialist franchise in pulmonary arterial\u00a0hypertension,\u00a0Ohtuvayre\u00a0has added\u00a0an\u00a0already marketed respiratory drug, and the current approval of\u00a0enlicitide\u00a0provides Merck an entry into the a lot bigger ldl cholesterol market.\u00a0\u00a0<\/p>\n
Winrevair\u00a0has supplied the strongest early validation. Merck gained\u00a0sotatercept\u00a0by its\u00a0$11.5 billion\u00a0acquisition\u00a0of Acceleron in 2021, earlier than the drug was authorized for pulmonary arterial hypertension (PAH). Launched within the U.S. as\u00a0Winrevair\u00a0in March 2024, it generated\u00a0$1.4 billion\u00a0in 2025, its first full yr in the marketplace.\u00a0<\/p>\n
The drug can be transferring past the inhabitants that supported its\u00a0preliminary\u00a0approval. Within the part 3 trial, Winrevair diminished the chance of demise, lung transplantation, or PAH-related hospitalization in sufferers with superior illness, supporting an\u00a0expanded U.S. indication\u00a0in October 2025.\u00a0\u00a0<\/p>\n
Winrevair\u00a0resembles the acquisition mannequin Merck is\u00a0making an attempt\u00a0to repeat elsewhere: purchase a clinically superior asset, then enhance its worth by\u00a0extra\u00a0trials,\u00a0indication\u00a0enlargement, and international commercialization.\u00a0\u00a0<\/p>\n
Ohtuvayre broadens Merck\u2019s place into respiratory illness. Merck\u00a0acquired\u00a0the drug with Verona Pharma after its U.S. launch for the upkeep therapy of persistent obstructive pulmonary illness (COPD).\u00a0\u00a0The product generated $178 million for Merck between the completion of the acquisition in October and the tip of 2025, whereas\u00a0Winrevair\u00a0continues to broaden in uncommon pulmonary illness.\u00a0\u00a0<\/p>\n
Enlicitide\u00a0extends the pillar towards a mass cardiovascular market.\u00a0Accredited by the FDA\u00a0this\u00a0week as\u00a0Lipfendra, it’s the first oral PCSK9 inhibitor, providing a once-daily pill towards a goal beforehand addressed by injectable antibodies.\u00a0<\/p>\n
In part 3,\u00a0enlicitide\u00a0lowered\u00a0LDL ldl cholesterol by 56% in contrast with placebo at\u00a024 weeks. It additionally outperformed established oral non-statin choices, together with ezetimibe and bempedoic acid.\u00a0<\/p>\n
Injectable PCSK9 therapies have\u00a0demonstrated\u00a0that the mechanism can produce substantial LDL reductions, however an oral model could also be simpler to introduce alongside statins and extra enticing to some sufferers and prescribers. A every day capsule will not be essentially simpler to stick to than an injection given each few weeks, and pricing and reimbursement will strongly affect uptake.\u00a0\u00a0<\/p>\n
Merck\u2019s oncology pipeline fragments past Keytruda<\/h2>\n
Keytruda\u2019s patent expiry doesn’t mark the tip of Merck\u2019s oncology technique. The corporate is utilizing the years earlier than biosimilar competitors arrives to reshape its most cancers enterprise round a number of applied sciences quite than a single immunotherapy. Whereas Keytruda\u00a0stays\u00a0the industrial engine, Merck is extending its attain into antibody-drug conjugates (ADCs), focused\u00a0therapies\u00a0and customized most cancers vaccines, making a portfolio that’s broader, but in addition extra fragmented.\u00a0<\/p>\n
The corporate continues to maneuver Keytruda into earlier phases of illness, the place sufferers are handled earlier than or after surgical procedure. On the similar time, the launch of the subcutaneous formulation, Keytruda\u00a0Qlex, gives a extra handy various to intravenous administration and will assist protect the franchise as\u00a0biosimilars\u00a0method. Keytruda additionally\u00a0stays\u00a0Merck\u2019s most well-liked mixture associate, permitting the corporate to pair its established checkpoint inhibitor with a lot of its next-generation oncology property.\u00a0<\/p>\n
The second a part of the technique has been constructed\u00a0largely by\u00a0exterior innovation and offers. Merck has assembled one of many trade\u2019s broadest ADC portfolios by partnerships with\u00a0Kelun-Biotech and Daiichi Sankyo, for example. These collaborations give the corporate entry to a number of targets, tumor\u00a0varieties,\u00a0and payload applied sciences, whereas permitting Keytruda to be evaluated alongside a number of of them. An instance of that is Merck\u2019s $700 million financing\u00a0settlement\u00a0with Blackstone Life Sciences to assist the event of\u00a0sacituzumab\u00a0tirumotecan\u00a0(sac-TMT).\u00a0<\/p>\n
On the similar time, Merck is investing in property that might finally stand independently of PD-1 inhibition.\u00a0Welireg\u00a0is a industrial instance of a focused remedy outdoors immuno-oncology, whereas Merck\u2019s acquisition of Terns added TERN-701 in persistent myeloid leukemia to a rising hematology pipeline that additionally consists of\u00a0bomedemstat,\u00a0nemtabrutinib\u00a0and\u00a0zilovertamab\u00a0vedotin. In the meantime,\u00a0its\u00a0collaboration\u00a0with Moderna on the customized most cancers vaccine\u00a0intismeran\u00a0autogene\u00a0is one other diversification past typical checkpoint inhibition, even when this system presently depends upon mixture with Keytruda.\u00a0<\/p>\n
Merck\u2019s oncology enterprise is turning into extra diversified, however not essentially much less depending on Keytruda. A lot of its most promising applications are nonetheless designed to enrich the checkpoint inhibitor quite than substitute it outright.\u00a0\u00a0<\/p>\n
Can Merck\u2019s immunology pipeline repeat the Keytruda playbook?<\/h2>\n
Merck\u2019s rising immunology technique is about whether or not it could actually take a single mechanism and prolong it throughout a number of illnesses, because it beforehand did with PD-1 inhibition. Its\u00a0$10.8 billion\u00a0acquisition\u00a0of Prometheus Biosciences in 2023 was\u00a0largely a\u00a0guess on\u00a0tulisokibart, an antibody concentrating on TL1A, a protein concerned in inflammatory and fibrotic pathways. The deal additionally added Prometheus\u2019s genetics and biomarker capabilities.\u00a0<\/p>\n
That funding acquired its most necessary validation in June 2026, when the part 3 ATLAS-UC induction trial\u00a0met its main and key secondary endpoints\u00a0in ulcerative colitis.\u00a0Tulisokibart\u00a0induced medical remission and improved endoscopic and histological measures after\u00a012 weeks, making it the primary anti-TL1A antibody to report optimistic part 3 leads to the illness.\u00a0\u00a0<\/p>\n
Merck is growing\u00a0tulisokibart\u00a0as greater than an ulcerative colitis therapy. A part 3 program is underway in Crohn\u2019s illness, whereas earlier-stage trials in rheumatological, dermatological and fibrotic circumstances together with rheumatoid arthritis, hidradenitis suppurativa and systemic sclerosis-associated interstitial lung illness are underway.\u00a0\u00a0<\/p>\n
The corporate can be starting so as to add different immunology mechanisms across the Prometheus platform. Its settlement with Dr. Falk Pharma secured international rights to the early-stage anti-CD30L antibody MK-8690 for $150 million upfront.\u00a0<\/p>\n
Pembrolizumab helped\u00a0set up\u00a0a brand new therapeutic class after which expanded quickly throughout tumor varieties. TL1A is already a aggressive subject, with Sanofi and Teva\u2019s\u00a0duvakitug\u00a0in part 3, Roche growing\u00a0afimkibart, and different corporations pursuing next-generation antibodies. Merck might have secured an early lead with the primary optimistic part 3 readout, however constructing a significant immunology franchise will depend upon whether or not\u00a0tulisokibart\u00a0can distinguish itself.\u00a0<\/p>\n
Merck\u2019s infectious illness pipeline: A quieter technique<\/h2>\n
The muse of Merck\u2019s infectious pipeline is\u00a0islatravir, which reached the U.S. market in April 2026 with\u00a0Idvynso, a once-daily mixture with\u00a0doravirine\u00a0for virologically suppressed adults. Merck is now making an attempt to increase the identical molecule into much less frequent regimens. Its once-weekly mixture with Gilead\u2019s lenacapavir\u00a0produced\u00a0optimistic part 3 leads to June 2026, whereas one other weekly mixture with\u00a0ulonivirine\u00a0is in part 2b improvement.\u00a0<\/p>\n
Merck can be wanting in the direction of prevention.\u00a0Alimatravir, a separate long-acting compound, is in part 3 as a once-monthly oral\u00a0PrEP\u00a0capsule. Present oral\u00a0PrEP\u00a0could be extremely efficient when taken constantly, however its real-world safety depends upon adherence. A month-to-month pill might\u00a0significantly scale back\u00a0the therapy burden.\u00a0<\/p>\n
Merck is making use of related logic to influenza by CD388, the central asset in its\u00a0$9.2 billion\u00a0acquisition of Cidara. The long-acting antiviral is being developed as a single-dose preventive supposed to guard high-risk individuals throughout an influenza season, no matter their immune response. It’s now in part 3.\u00a0<\/p>\n
Merck after Keytruda: a broader portfolio\u00a0<\/h2>\n
Merck\u2019s response to the approaching Keytruda patent cliff is now seen. It’s assembling a number of franchises that might collectively assist the corporate throughout oncology, cardio-pulmonary drugs,\u00a0immunology,\u00a0and infectious illness.\u00a0<\/p>\n
Winrevair\u00a0and Ohtuvayre give Merck two differentiated cardio-respiratory merchandise.\u00a0Tulisokibart\u00a0might anchor a brand new immunology franchise. ADCs, focused\u00a0therapies\u00a0and customized vaccines are increasing oncology past PD-1 inhibition, whereas Merck\u2019s infectious illness applications share a quieter technological emphasis on longer-lasting therapy and prevention.\u00a0<\/p>\n
But Merck\u2019s diversification on the pipeline degree doesn’t imply diversification on the income degree. Keytruda and Keytruda\u00a0Qlex\u00a0generated\u00a0$31.7 billion\u00a0in 2025, near half of Merck\u2019s complete gross sales. Gardasil contributed one other\u00a0$5.2 billion\u00a0regardless of its sharp decline in China. By comparability, the corporate\u2019s newer merchandise are nonetheless measured in tons of of tens of millions or low single-digit billions.\u00a0<\/p>\n
Merck now wants a number of applications to succeed throughout completely different illnesses, improvement\u00a0phases,\u00a0and industrial fashions. That technique has additionally been costly. Merck paid\u00a0$10.8 billion for Prometheus,\u00a0$10 billion for Verona, and\u00a0$9.2 billion for\u00a0Cidara, whereas persevering with to commit substantial capital by licensing agreements and oncology collaborations. These investments present entry to differentiated science, however in addition they place larger strain on Merck to broaden indications, combine\u00a0acquired\u00a0property, and commercialize these property.\u00a0<\/p>\n
The corporate has diminished the chance of relying on one scientific mechanism by rising its dependence on dealmaking and portfolio execution. The post-Keytruda Merck could also be broader and extra resilient, however it is going to even be extra difficult and fewer reliant on one product, and extra reliant on dozens of medical, regulatory, and industrial selections going sufficiently properly on the similar time.\u00a0<\/p>\n<\/div>\n
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Like many huge pharma corporations presently, Merck\u2019s greatest problem within the subsequent few years is the patent cliff. Merck has spent years getting ready for the lack of exclusivity dealing with Keytruda, however the scale of the issue continues to develop. Keytruda and its subcutaneous formulation Keytruda\u00a0Qlex\u00a0generated\u00a0round\u00a0$31.7 billion\u00a0in 2025,\u00a0practically half\u00a0of Merck\u2019s complete gross sales, whereas […]<\/p>\n","protected":false},"author":1,"featured_media":3124,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[3550,1737,1139],"class_list":["post-3122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-keytruda","tag-merck","tag-pipeline"],"yoast_head":"\n
Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24<\/title>\n<meta name=\"description\" content=\"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-31T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-01T02:59:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Merck after Keytruda: what the pipeline seems to be like\u00a0\",\"datePublished\":\"2026-07-31T13:00:00+00:00\",\"dateModified\":\"2026-08-01T02:59:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/\"},\"wordCount\":2070,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/scott-graham-5fNmWej4tAA-unsplash.jpg\",\"keywords\":[\"Keytruda\",\"Merck\",\"pipeline\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/\",\"name\":\"Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/scott-graham-5fNmWej4tAA-unsplash.jpg\",\"datePublished\":\"2026-07-31T13:00:00+00:00\",\"dateModified\":\"2026-08-01T02:59:03+00:00\",\"description\":\"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/scott-graham-5fNmWej4tAA-unsplash.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/scott-graham-5fNmWej4tAA-unsplash.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/31\\\/merck-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck after Keytruda: what the pipeline seems to be like\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24","description":"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24","og_description":"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/","og_site_name":"Future News 24","article_published_time":"2026-07-31T13:00:00+00:00","article_modified_time":"2026-08-01T02:59:03+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Merck after Keytruda: what the pipeline seems to be like\u00a0","datePublished":"2026-07-31T13:00:00+00:00","dateModified":"2026-08-01T02:59:03+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/"},"wordCount":2070,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","keywords":["Keytruda","Merck","pipeline"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/","name":"Merck after Keytruda: what the pipeline seems to be like\u00a0 - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","datePublished":"2026-07-31T13:00:00+00:00","dateModified":"2026-08-01T02:59:03+00:00","description":"Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/scott-graham-5fNmWej4tAA-unsplash.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/31\/merck-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Merck after Keytruda: what the pipeline seems to be like\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=3122"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3122\/revisions"}],"predecessor-version":[{"id":3123,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/3122\/revisions\/3123"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/3124"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=3122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=3122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=3122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}